newborn screening
Rebranded GeneDx Bets Future on Whole-Exome, Whole-Genome Sequencing in Pediatric Rare Disease
Premium
After dropping underdeveloped Sema4 business lines but emphasizing the Centrellis informatics platform, the new GeneDx expects to reach profitability by 2025.
State labs and commercial companies see rising spinal muscular atrophy test volumes as screening programs launch in US states and European countries, among others.
The UK government said it will also invest £26 million to support cancer genomics research, and an additional £22 million to improve genomic data diversity.
CEO and Cofounder İbrahim Çağrı Kurt discussed the new test during a presentation at Slush, an annual startup conference held in Helsinki this week.
PerkinElmer Nabs Authorization for Molecular SCID/SMA Test in Newborns
The firm said its assay for spinal muscular atrophy and severe combined immunodeficiency can aid early identification and treatment of those potentially fatal diseases.